MA32553B1 - Composition pharmaceutique solide - Google Patents

Composition pharmaceutique solide

Info

Publication number
MA32553B1
MA32553B1 MA33604A MA33604A MA32553B1 MA 32553 B1 MA32553 B1 MA 32553B1 MA 33604 A MA33604 A MA 33604A MA 33604 A MA33604 A MA 33604A MA 32553 B1 MA32553 B1 MA 32553B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
solid pharmaceutical
diuretic
compound
formula
Prior art date
Application number
MA33604A
Other languages
Arabic (ar)
English (en)
Inventor
Yutaka Tanoue
Junya Nomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32553(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32553B1 publication Critical patent/MA32553B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne une préparation solide contenant un composé de formule (i) dans lequel chaque symbole est tel que défini dans la description, ou un sel de celui-ci, un agent de contrôle de ph et un diurétique, qui présente une stabilité et une propriété de dilution supérieures du composé de formule (i) et du diurétique.
MA33604A 2008-07-31 2011-02-11 Composition pharmaceutique solide MA32553B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8520108P 2008-07-31 2008-07-31
US8562708P 2008-08-01 2008-08-01
PCT/JP2009/063833 WO2010013835A2 (fr) 2008-07-31 2009-07-29 Composition pharmaceutique solide

Publications (1)

Publication Number Publication Date
MA32553B1 true MA32553B1 (fr) 2011-08-01

Family

ID=41610805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33604A MA32553B1 (fr) 2008-07-31 2011-02-11 Composition pharmaceutique solide

Country Status (26)

Country Link
US (1) US9169238B2 (fr)
EP (1) EP2310385B1 (fr)
JP (1) JP5635491B2 (fr)
KR (1) KR20110038145A (fr)
CN (1) CN102164918B (fr)
AR (1) AR072883A1 (fr)
AU (1) AU2009277455A1 (fr)
BR (1) BRPI0916847A2 (fr)
CA (1) CA2732018C (fr)
CL (1) CL2011000187A1 (fr)
CO (1) CO6341633A2 (fr)
CR (1) CR20110111A (fr)
DO (1) DOP2011000032A (fr)
EA (1) EA201170273A1 (fr)
EC (1) ECSP11010856A (fr)
GE (1) GEP20146062B (fr)
IL (1) IL210819A0 (fr)
MA (1) MA32553B1 (fr)
MX (1) MX2011001150A (fr)
NZ (1) NZ590948A (fr)
PE (1) PE20110551A1 (fr)
PT (1) PT2310385T (fr)
TW (1) TW201008915A (fr)
UY (1) UY32017A (fr)
WO (1) WO2010013835A2 (fr)
ZA (1) ZA201100871B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
WO2010075347A2 (fr) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
JP2015526477A (ja) * 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
JP6935301B2 (ja) * 2016-11-18 2021-09-15 花王株式会社 モノハロゲノアミン製造用被覆粒子群
IN202021028444A (fr) * 2020-07-03 2022-01-28

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) * 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
CA2125251C (fr) 1993-06-07 2005-04-26 Yoshiyuki Inada Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
AU2001232348A1 (en) 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
JP2001294524A (ja) 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd アセトアミノフェン配合内服固形製剤
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US20040147605A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Drug preparations
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
EP1648515B1 (fr) 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Combinaisons de chlorthalidone
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7625940B2 (en) * 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
WO2006028007A1 (fr) 2004-09-06 2006-03-16 Kowa Co., Ltd. Medicament contre les maladies glomerulaires
US20070049636A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
AU2005315855A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
EP1863801B1 (fr) 2005-03-30 2010-09-29 Takeda Pharmaceutical Company Limited Derive de benzimidazole et utilisation de celui-ci
WO2006124713A2 (fr) 2005-05-13 2006-11-23 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
CA2660427A1 (fr) 2006-08-10 2008-02-14 Takeda Pharmaceutical Company Limited Composition pharmaceutique
WO2008045006A1 (fr) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations de candésartan
WO2008068217A2 (fr) 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Composition pharmaceutique
NZ579851A (en) 2007-03-28 2012-02-24 Takeda Pharmaceutical Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
RU2010104960A (ru) 2007-08-01 2011-09-10 Тева Фармасьютикал Индастриес Лтд. (Il) Фармацевтическая композиция кандесартана
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2010075347A2 (fr) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone

Also Published As

Publication number Publication date
ECSP11010856A (es) 2011-03-31
IL210819A0 (en) 2011-04-28
DOP2011000032A (es) 2011-02-28
UY32017A (es) 2010-02-26
CO6341633A2 (es) 2011-11-21
CN102164918A (zh) 2011-08-24
MX2011001150A (es) 2011-03-29
GEP20146062B (en) 2014-03-25
CL2011000187A1 (es) 2011-06-24
CN102164918B (zh) 2014-05-07
KR20110038145A (ko) 2011-04-13
EP2310385B1 (fr) 2017-06-07
ZA201100871B (en) 2012-05-30
JP2011529444A (ja) 2011-12-08
PT2310385T (pt) 2017-09-11
CR20110111A (es) 2011-04-28
EA201170273A1 (ru) 2011-08-30
WO2010013835A3 (fr) 2010-06-10
US20110123615A1 (en) 2011-05-26
AU2009277455A1 (en) 2010-02-04
NZ590948A (en) 2012-06-29
EP2310385A2 (fr) 2011-04-20
US9169238B2 (en) 2015-10-27
TW201008915A (en) 2010-03-01
PE20110551A1 (es) 2011-09-02
WO2010013835A2 (fr) 2010-02-04
BRPI0916847A2 (pt) 2016-02-10
CA2732018C (fr) 2017-07-04
CA2732018A1 (fr) 2010-02-04
AR072883A1 (es) 2010-09-29
JP5635491B2 (ja) 2014-12-03

Similar Documents

Publication Publication Date Title
MA32553B1 (fr) Composition pharmaceutique solide
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
NO20071901L (no) Substituerte bisykliske imidazo-3-ylamin sammensetninger
NO20063449L (no) Substituerte heterocykler og deres anvendelse
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
ME01284B (fr) Composés organiques
MA32903B1 (fr) Inhibiteurs de proteine-kinases
UY29448A1 (es) Compuestoss inhibidores de dipeptidil peptidasa-iv, metodos de preparación de los mismos y composiciones farmacéuticas conteniendolos como principios activos.
MA30890B1 (fr) Compose indole
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA35184B1 (fr) Antagonistes de trpv4
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
NO20075647L (no) Kjemiske forbindelser
SG163585A1 (en) Melanocortin receptor ligands
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
BRPI0618589B8 (pt) composto de oxazol, composição farmacêutica compreendendo o referido composto, processos de fabricação e usos dos mesmos
DE602005003128D1 (de) Chinazolinon-derivate als vanilloid-antagonisten
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MA34723B1 (fr) Compositions et méthodes de traitement de la myélofibrose